BioCryst Pharmaceuticals (BCRX) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed Perrigo (PRGO) over the past year, gaining 20.9% versus a loss of 32.9%. Over five years, BCRX leads with a -44.5% price change compared with -67.5% for PRGO. BioCryst Pharmaceuticals is the larger company by market cap ($2.12 billion vs $2.01 billion), about 1.1 times the size.
On valuation, Perrigo trades at a lower forward P/E (6.0x vs 8.8x for BioCryst Pharmaceuticals). Perrigo pays a dividend yielding 8.00%, while BioCryst Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | PRGO |
|---|---|---|
| Share price | $8.29 | $14.50 |
| Market cap | $2.12B | $2.01B |
| 1-day change | -1.31% | -0.34% |
| YTD return | +7.69% | +4.53% |
| 1-year return | +20.86% | -32.89% |
| 5-year return | -44.48% | -67.46% |
| Forward P/E | 8.82 | 6.05 |
| EPS (TTM) | $-1.40 | $-12.28 |
| Dividend yield | 0.00% | 8.00% |
| Annual dividend | $0.00 | $1.16 |
| 52-week high | $11.22 | $22.02 |
| 52-week low | $6.00 | $9.23 |
| Distance from 52-week high | -26.11% | -34.15% |
| Analyst consensus | buy | none |
| Avg. price target upside | +150.06% | +13.79% |
| Average volume | 4.11M | 2.80M |
| Shares outstanding | 255.54M | 138.37M |
| Employees | 435 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed PRGO by 53.8 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (8.00% vs 0.00%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
BCRX vs PRGO FAQ
Which is bigger, BioCryst Pharmaceuticals or Perrigo?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.12B compared with $2.01B for Perrigo (PRGO).
Which stock has performed better over the past year, BCRX or PRGO?
BCRX returned +20.86% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BioCryst Pharmaceuticals or Perrigo?
Perrigo pays a dividend yielding 8.00%, while BioCryst Pharmaceuticals does not currently pay a regular dividend.
Are BioCryst Pharmaceuticals and Perrigo in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Perrigo.